Clearmind Medicine Inc. (NASDAQ: CMND) announced the continuation of participant enrollment for the third cohort of its ongoing Phase I/IIa clinical trial evaluating CMND-100 for alcohol use disorder treatment.

The Vancouver-based biotech company reported that recruitment follows positive topline results from the second cohort, which demonstrated continued safety and tolerability. The company's Data and Safety Monitoring Board reviewed the data and provided unanimous approval to proceed with enrollment.

The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe alcohol use disorder. Participant recruitment for the third cohort is taking place at Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center.

CMND-100 is described as a proprietary non-hallucinogenic MEAI-based oral drug candidate. The FDA has approved the clinical trial.

"Building on the encouraging results from our first and second cohort, we are excited on progressing with the clinical trial at these prestigious institutions," said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine.

Clearmind is a clinical-stage pharmaceutical biotech company focused on developing psychedelic-derived therapeutics. The company's intellectual portfolio consists of nineteen patent families, including 31 granted patents.

The information is based on a company press release statement.